| Composition of certain financial statement captions |
|
|
|
|
|
|
|
|
|
(In thousands) |
June 30,
2013 |
|
December 31,
2012
|
Accounts receivable, net: |
|
|
|
Accounts receivable |
$ |
23,135 |
|
|
$ |
21,636 |
|
Less: allowance for doubtful accounts |
(908 |
) |
|
(474 |
) |
|
$ |
22,227 |
|
|
$ |
21,162 |
|
Inventories, net: |
|
|
|
Finished products |
$ |
15,169 |
|
|
$ |
17,963 |
|
Work in-process |
1,253 |
|
|
688 |
|
Raw materials |
4,721 |
|
|
4,923 |
|
Less: inventory reserve |
(1,365 |
) |
|
(1,313 |
) |
|
$ |
19,778 |
|
|
$ |
22,261 |
|
Intangible assets, net: |
|
|
|
Technologies |
$ |
52,796 |
|
|
$ |
52,810 |
|
Customer relationships |
22,839 |
|
|
23,088 |
|
Product registrations |
9,690 |
|
|
9,637 |
|
Tradenames |
3,683 |
|
|
3,746 |
|
Covenants not to compete |
8,660 |
|
|
8,662 |
|
Other |
1,180 |
|
|
367 |
|
Less: accumulated amortization |
(19,073 |
) |
|
(14,072 |
) |
|
$ |
79,775 |
|
|
$ |
84,238 |
|
Accrued expenses: |
|
|
|
Income taxes payable |
$ |
2,421 |
|
|
$ |
1,614 |
|
Deferred revenue |
3,903 |
|
|
1,518 |
|
Clinical trials |
315 |
|
|
50 |
|
Professional fees |
933 |
|
|
675 |
|
Employee benefits |
3,972 |
|
|
3,319 |
|
Deferred acquisition payments, net of discount |
5,432 |
|
|
6,172 |
|
Contingent consideration |
5,298 |
|
|
5,126 |
|
Interest payable related to the Notes |
2,275 |
|
|
— |
|
Other |
6,496 |
|
|
6,182 |
|
|
$ |
31,045 |
|
|
$ |
24,656 |
|
Other long-term liabilities: |
|
|
|
Contingent consideration – Cytochroma |
$ |
49,784 |
|
|
$ |
— |
|
Contingent consideration – Farmadiet |
529 |
|
|
532 |
|
Contingent consideration – OPKO Diagnostics |
12,746 |
|
|
11,310 |
|
Contingent consideration – FineTech |
— |
|
|
2,578 |
|
Contingent consideration – CURNA |
549 |
|
|
510 |
|
Deferred acquisition payments, net of discount |
3,983 |
|
|
3,931 |
|
Mortgages and other debts payable |
3,636 |
|
|
5,150 |
|
Deferred tax liabilities |
7,185 |
|
|
9,777 |
|
Other, including deferred revenue |
2,191 |
|
|
380 |
|
|
$ |
80,603 |
|
|
$ |
34,168 |
|
|